Overview:
This test evaluates the presence and characteristics of abnormal lymphocytes in peripheral blood to aid in diagnosis and monitoring of Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and other Chronic Lymphoproliferative Disorders (CLPD). It typically involves blood smear examination, flow cytometry immunophenotyping, and sometimes molecular studies.

Risk Assessment:

• Risk factors for CLL/CLPD include older age, family history, and certain environmental exposures.

• The test helps identify clonal B-cell populations indicating leukemia/lymphoma presence and progression risk.

• Early detection allows timely management and monitoring for complications like infections, anemia, or progression to aggressive lymphoma.

Normal Range:

• Normal lymphocyte counts vary by lab but generally:

  • Absolute lymphocyte count: 1,000 – 4,800 cells/µL

  • Normal lymphocytes show polyclonal pattern without abnormal immunophenotypes.

Interpretation:

• Presence of increased lymphocytes with characteristic immunophenotype (CD5+, CD19+, CD20dim, CD23+) suggests CLL.
• Clonality confirmation (monoclonal B-cell population) supports diagnosis.
• Abnormal cells morphology on blood smear, along with flow cytometry results, confirm disease.
• Results guide staging, prognosis, and therapy decisions.

Sample Type:

• Peripheral blood (usually EDTA anticoagulated whole blood)